ARS Pharmaceuticals (SPRY) announced that Health Canada has granted approval for neffy 2 mg for the emergency treatment of allergic reactions in adults and children who weigh 30 kg or more. ARS Pharma entered into an exclusive licensing agreement with ALK- Abello A/S in November 2024, providing ALK with exclusive rights to commercialize neffy in Europe, Canada, United Kingdom and certain other geographies outside of the U.S. Under the terms of the agreement, ARS Pharma has received upfront and milestone payments of $155M to date and is eligible to receive up to an additional $310M in regulatory and sales milestones, as well as tiered, double-digit royalties in the teens on net sales in licensed geographies. ARS Pharma will be responsible for manufacturing and supplying neffy to ALK in Canada and expects neffy to be available in the summer of 2026. ARS Pharma anticipates filing for approval of neffy 1 mg dose for children greater than 15 kg and less than 30 kg with Health Canada by this summer.
Meet Samuel – Your Personal Investing Prophet
- Start a conversation with TipRanks’ trusted, data-backed investment intelligence
- Ask Samuel about stocks, your portfolio, or the market and get instant, personalized insights in seconds
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on SPRY:
- ARS Pharmaceuticals initiated with an Outperform at Northland
- Northland starts disruptor ARS Pharmaceuticals with an Outperform
- Ars Pharmaceuticals Earnings Call Highlights Neffy’s Early Traction
- ARS Pharmaceuticals receives FDA approval to remove neffy 1 mg age requirement
- Nasus Pharma’s Positive Phase 2 Data Validates the Speed and Reliability of the NS002 Powder Platform